Aim immunotech announces first healthy subjects dosed in phase 1 intranasal ampligen clinical study

Marks important milestone towards development of ampligen as a potential prophylaxis or treatment for covid-19 and other respiratory viral diseases marks important milestone towards development of ampligen as a potential prophylaxis or treatment for covid-19 and other respiratory viral diseases
AIM Ratings Summary
AIM Quant Ranking